In CML, mutations in the kinase domain of the BCR::ABL1 fusion gene may induce resistance to tyrosine kinase inhibitors, as was illustrated by case 744, containing multiple such mutations. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.